93 related articles for article (PubMed ID: 24580635)
1. Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.
Castellano S; Taliani S; Viviano M; Milite C; Da Pozzo E; Costa B; Barresi E; Bruno A; Cosconati S; Marinelli L; Greco G; Novellino E; Sbardella G; Da Settimo F; Martini C
J Med Chem; 2014 Mar; 57(6):2413-28. PubMed ID: 24580635
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
Castellano S; Taliani S; Milite C; Pugliesi I; Da Pozzo E; Rizzetto E; Bendinelli S; Costa B; Cosconati S; Greco G; Novellino E; Sbardella G; Stefancich G; Martini C; Da Settimo F
J Med Chem; 2012 May; 55(9):4506-10. PubMed ID: 22489952
[TBL] [Abstract][Full Text] [Related]
3. TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation.
Bertomeu T; Zvereff V; Ibrahim A; Zehntner SP; Aliaga A; Rosa-Neto P; Bedell BJ; Falardeau P; Gourdeau H
Biochem Pharmacol; 2010 Nov; 80(10):1572-9. PubMed ID: 20655882
[TBL] [Abstract][Full Text] [Related]
4. GQSAR modeling and combinatorial library generation of 4-phenylquinazoline-2-carboxamide derivatives as antiproliferative agents in human Glioblastoma tumors.
Goswami D; Goyal S; Jamal S; Jain R; Wahi D; Grover A
Comput Biol Chem; 2017 Aug; 69():147-152. PubMed ID: 28420545
[TBL] [Abstract][Full Text] [Related]
5. TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance.
Costa B; Da Pozzo E; Giacomelli C; Taliani S; Bendinelli S; Barresi E; Da Settimo F; Martini C
Apoptosis; 2015 Mar; 20(3):383-98. PubMed ID: 25413799
[TBL] [Abstract][Full Text] [Related]
6. Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein.
Cosimelli B; Simorini F; Taliani S; La Motta C; Da Settimo F; Severi E; Greco G; Novellino E; Costa B; Da Pozzo E; Bendinelli S; Martini C
Eur J Med Chem; 2011 Sep; 46(9):4506-20. PubMed ID: 21824692
[TBL] [Abstract][Full Text] [Related]
7. Derivatives of the pyrazolo[1,5-a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma.
Werry EL; King VA; Barron ML; Banister SD; Sokias R; Kassiou M
Eur J Pharm Sci; 2017 Jan; 96():186-192. PubMed ID: 27658888
[TBL] [Abstract][Full Text] [Related]
8. 2-Phenylimidazo[1,2-a]pyridine-containing ligands of the 18-kDa translocator protein (TSPO) behave as agonists and antagonists of steroidogenesis in a mouse leydig tumor cell line.
Midzak A; Denora N; Laquintana V; Cutrignelli A; Lopedota A; Franco M; Altomare CD; Papadopoulos V
Eur J Pharm Sci; 2015 Aug; 76():231-7. PubMed ID: 26002041
[TBL] [Abstract][Full Text] [Related]
9. Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein.
Margiotta N; Denora N; Ostuni R; Laquintana V; Anderson A; Johnson SW; Trapani G; Natile G
J Med Chem; 2010 Jul; 53(14):5144-54. PubMed ID: 20568783
[TBL] [Abstract][Full Text] [Related]
10. Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization.
Taliani S; Da Pozzo E; Bellandi M; Bendinelli S; Pugliesi I; Simorini F; La Motta C; Salerno S; Marini AM; Da Settimo F; Cosimelli B; Greco G; Novellino E; Martini C
J Med Chem; 2010 May; 53(10):4085-93. PubMed ID: 20438080
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationships of novel benzoxazolone derivatives as 18 kDa translocator protein (TSPO) ligands.
Fukaya T; Kodo T; Ishiyama T; Kakuyama H; Nishikawa H; Baba S; Masumoto S
Bioorg Med Chem; 2012 Sep; 20(18):5568-82. PubMed ID: 22884355
[TBL] [Abstract][Full Text] [Related]
12. Repeated administration of AC-5216, a ligand for the 18 kDa translocator protein, improves behavioral deficits in a mouse model of post-traumatic stress disorder.
Qiu ZK; Zhang LM; Zhao N; Chen HX; Zhang YZ; Liu YQ; Mi TY; Zhou WW; Li Y; Yang RF; Xu JP; Li YF
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():40-6. PubMed ID: 23624119
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO).
Milite C; Barresi E; Da Pozzo E; Costa B; Viviano M; Porta A; Messere A; Sbardella G; Da Settimo F; Novellino E; Cosconati S; Castellano S; Taliani S; Martini C
J Med Chem; 2017 Sep; 60(18):7897-7909. PubMed ID: 28858490
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and structure-activity relationship of novel tricyclic benzimidazolone derivatives as potent 18 kDa translocator protein (TSPO) ligands.
Fukaya T; Kodo T; Ishiyama T; Nishikawa H; Baba S; Masumoto S
Bioorg Med Chem; 2013 Mar; 21(5):1257-67. PubMed ID: 23352481
[TBL] [Abstract][Full Text] [Related]
15. TSPO as a target for glioblastoma therapeutics.
Werry EL; Barron ML; Kassiou M
Biochem Soc Trans; 2015 Aug; 43(4):531-6. PubMed ID: 26551689
[TBL] [Abstract][Full Text] [Related]
16. Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.
Daniele S; La Pietra V; Barresi E; Di Maro S; Da Pozzo E; Robello M; La Motta C; Cosconati S; Taliani S; Marinelli L; Novellino E; Martini C; Da Settimo F
J Med Chem; 2016 May; 59(10):4526-38. PubMed ID: 27050782
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Jendrossek V; Hammersen K; Erdlenbruch B; Kugler W; Krügener R; Eibl H; Lakomek M
Cancer Chemother Pharmacol; 2002 Jul; 50(1):71-9. PubMed ID: 12111115
[TBL] [Abstract][Full Text] [Related]
18. Effects of 18-kDa translocator protein knockdown on gene expression of glutamate receptors, transporters, and metabolism, and on cell viability affected by glutamate.
Veenman L; Bode J; Gaitner M; Caballero B; Peʼer Y; Zeno S; Kietz S; Kugler W; Lakomek M; Gavish M
Pharmacogenet Genomics; 2012 Aug; 22(8):606-19. PubMed ID: 22732722
[TBL] [Abstract][Full Text] [Related]
19. First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO).
Narlawar R; Werry EL; Scarf AM; Hanani R; Chua SW; King VA; Barron ML; Martins RN; Ittner LM; Rendina LM; Kassiou M
J Med Chem; 2015 Nov; 58(21):8743-9. PubMed ID: 26461041
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma.
Daniele S; Taliani S; Da Pozzo E; Giacomelli C; Costa B; Trincavelli ML; Rossi L; La Pietra V; Barresi E; Carotenuto A; Limatola A; Lamberti A; Marinelli L; Novellino E; Da Settimo F; Martini C
Sci Rep; 2014 Apr; 4():4749. PubMed ID: 24756113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
